^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Reqorsa (quaratusugene ozeplasmid) (Apoptosis stimulant, Immunomodulator, Gene transference, TUSC2 gene stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination with Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published date:
01/03/2022
Excerpt:
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX)...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda.
